Vimarsana
Biggest News Aggregation in the World

Page 9 - Mark Neumann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Mark Neumann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Mark Neumann Today - Breaking & Trending Today

Stories and Rhymes (Children's Concert for Children of All Ages) -- Brightmusic Festival Concert 2 - Vimarsana News

Stories and Rhymes (Children's Concert for Children of All Ages) -- Brightmusic Festival Concert 2

Oklahoma City -- Today (Sunday, June 11), the Brightmusic Summer Festival continues at First Baptist Church in Oklahoma City.

Osterweis Capital Management Inc. Acquires 15,855 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - Vimarsana News

Osterweis Capital Management Inc. Acquires 15,855 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Osterweis Capital Management Inc. grew its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 37.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 57,750 shares of the biopharmaceutical company’s stock after acquiring an additional 15,855 shares during the quarter. Osterweis Capital Management Inc. […]

Analysts Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $74.45 - Vimarsana News

Analysts Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $74.45

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) have been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price […]

Guidewire Software (NYSE:GWRE) Now Covered by StockNews.com - Vimarsana News

Guidewire Software (NYSE:GWRE) Now Covered by StockNews.com

StockNews.com began coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Rating) in a research note issued to investors on Thursday. The firm issued a hold rating on the biopharmaceutical company’s stock. ITCI has been the topic of several other reports. Canaccord Genuity Group upped their price target on Intra-Cellular Therapies from $93.00 to $98.00 […]

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2023 Earnings Call Transcript - Vimarsana News

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q1 2023 Earnings Call Transcript

Operator: Good morning and welcome to Intra-Cellular Therapies First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.